SANOFI CONS HEALTHC IND L (SANOFICONR) Fair Value & Analysis
Healthcare · IN · Market cap ₹107B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from ₹1,896 to ₹2,031 (+7.1%) since Aug 8, 2026. Share price −4.5% over the past month.
A strong business, but screening 53% overvalued on our models.
What matters now
- A high-quality business (quality 89/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (₹1,324 to ₹4,381). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (23 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
23‑month range ₹3,939 – ₹5,610 · fair‑value band ₹1,324 – ₹4,381 · the ₹4,363 price screens above the ₹2,031 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
SANOFI CONS HEALTHC IND L (SANOFICONR) currently trades at ₹4,363, while our model-based Fair Value estimate is ₹2,031, implying the stock looks roughly 53.5% overvalued today. The Quality Score stands at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, SANOFI CONS HEALTHC IND L generated revenue of ₹9.3B at a net margin of 27.6%. Revenue grew 32.8% year over year. It earns a return on equity of 73.1%. The balance sheet holds a net cash position of ₹3.5B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹1,324 (bear case) to ₹4,381 (bull case); at ₹4,363, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -53%, SANOFICONR screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹3,370) versus Asset-Based (₹111.71). Highest evidence: Residual Income (76).
Notify me when SANOFICONR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 84 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and …
Full company description
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2023 – FY2025 · reported fiscal years
SANOFI CONS HEALTHC IND L reported revenue of ₹8.8B in FY2025 versus ₹5.4B in FY2023, a compound +27.0%/yr. Reported net income was ₹2.4B in FY2025, compounding +20.7%/yr from FY2023.
SANOFICONR screens 53% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,220 | $389.47 | -68% |
| Johnson & Johnson, JNJ | $260.86 | $169.04 | -35% |
| AbbVie Inc ABBV | $248.76 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €240.14 | -39% |
| Merck & Co MRK | €115.42 | €118.21 | +2% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| AstraZeneca PLC AZN | $158.50 | $127.32 | -20% |
| Novo Nordisk A/S NOVOB | kr 299.50 | kr 409.46 | +37% |
| Sanofi SNYN | 770.00 MXN | 1,041 MXN | +35% |
| GSK plc GSKN | 917.00 MXN | 879.08 MXN | -4% |
Compare SANOFI CONS HEALTHC IND L with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SANOFI CONS HEALTHC IND L (SANOFICONR) overvalued or undervalued?
What is the fair value of SANOFICONR?
What is the quality score of SANOFICONR?
What is the revenue of SANOFI CONS HEALTHC IND L (SANOFICONR)?
What is the net profit margin of SANOFICONR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SANOFI CONS HEALTHC IND L and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.